Current Setup & Catalysts
Current Setup & Catalysts — Molina Healthcare (MOH)
1. Current Setup in One Page
The stock is trading around $198 with a constructive recent tape (Q1 2026 beat, 50/200 golden cross on 2026-06-02, MCR step-down from 91.7% to 91.1%) layered on an unresolved credibility ledger (Hindlemann securities class action over Feb–Jul 2025 disclosures, S&P Negative outlook, covenant relief through Q3 2027). The market spent the last six months repricing a 55% earnings reset and is now in cycle-bottom debate — Q1 results, Florida sole-source, Illinois HealthChoice award, and the BofA "rare double upgrade" all argue trough is in; CLO insider selling, the $93M Bright Health impairment, and a $5 FY2026 EPS guide argue the recovery window is still 18–24 months long. The next hard test is the Q2 2026 earnings print on Wednesday, July 22, 2026 (call 7/23). The 5-to-10-year underwriting question — does the moat protect a $40–42B revenue base post-OBBBA — is decided by the Washington Medicaid RFP filing window in Q4 2026 and the Q3 2026 consolidated MCR print, not by any single quarter's headline beat or miss.
Recent Setup Rating
Hard-Dated Catalysts (next 6mo)
High-Impact Catalysts (next 6mo)
Days to Next Hard Date (Q2 print)
Price (2026-06-10)
FY2025 Consolidated MCR
Q1 2026 Consolidated MCR
FY2026 Adj EPS Floor ($)
The single highest-impact near-term event is not Q2. It is the Q3 2026 print (October 2026). Both the bull (MCR ≤91.0% pairs with Florida live) and the bear (MCR ≥92.6% confirms reserves were re-set light) converge on the Q3 number as the decisive cycle read. Q2 is a meaningful checkpoint; Q3 is the underwriting verdict.
2. What Changed in the Last 3-6 Months
The recent setup is dominated by the Q1 2026 beat reversing the Q4 2025 reset, the May 8 Investor Day reframing the 5-to-10-year EPS bridge, and the mixed insider/litigation signal that has prevented the cycle-turn narrative from fully consolidating.
Recent narrative arc. Six months ago the debate was whether the FY2025 reserve-set was structurally light (Hindlemann complaint), how deep the FY2026 guide would land (Q4 2025 reset answered: $5 floor), and whether the lender-implied 24-month stress window was the right frame (Feb 2026 covenant amendment forced that conversation). Today the debate has narrowed: investors agree the 2026 guide is the floor and accept the Florida + Illinois + Mississippi RFP wins as proof the franchise still works at the state agency level. What has not been resolved: whether Medicaid rate updates are actually catching trend (Q2/Q3 prints), whether the Hindlemann motion-to-dismiss will survive (which would re-rate management credibility), whether the CLO selling signals private knowledge or routine portfolio behavior, and whether the OBBBA work-requirement implementation lands at the 15% or 20% end of the management range.
3. What the Market Is Watching Now
The five items above are the live agenda. Notice that only one of them (Q2/Q3 MCR) is a single quarterly print — the rest are multi-quarter signals that resolve through 2027. That is the right framing: the market is no longer trading the next 30 days, it is trading the cycle. A clean Q2 beat would extend the rally; a clean Q2 miss would re-open the FY2025 credibility ledger. Neither resolves the underwriting case.
4. Ranked Catalyst Timeline
Ranked by decision value to a hedge-fund PM, not by chronology. Items inside the next six months unless flagged as beyond-six-month context.
The ranking puts Q3 2026 above Q2 2026 intentionally. Q2 is the first hard date and will move the stock, but the bull/bear cases converge on Q3 as the verdict: bull primary catalyst is "Q3 MCR below 91.0% paired with Florida going live," bear primary trigger is "Q3 MCR at or above 92.6%." If you only get to watch one print, watch Q3. The Washington RFP filing (#3) is the only catalyst inside the next six months that updates the 5-to-10-year moat thesis directly — even though the award doesn't come until 2027.
5. Impact Matrix
The matrix below isolates the catalysts that actually resolve the investment debate because they update a durable thesis variable. Catalysts that move estimates or sentiment but not the underwriting case are excluded.
The matrix isolates one near-term-evidence catalyst (Hindlemann MTD). Every other item updates a long-term driver: cycle MCR cadence, RFP incumbency, post-OBBBA revenue base, capital allocation discipline. The market is correctly trading the cycle, not the next print — the framing that makes Q2 a "decision catalyst" overstates how much one quarter changes the underwriting.
6. Next 90 Days
The 90-day window (through approximately 2026-09-09) contains exactly one hard-dated set-piece event and a few continuous watchpoints. The first truly decisive event is outside the window — the Q3 2026 print in October.
The 90-day calendar is thin. Exactly one hard-dated set-piece (Q2 print on 7/22). The most decision-relevant event in the next six months — Q3 MCR — falls in October, outside this window. The 90-day setup is asymmetric: a Q2 beat would extend the recovery and lift consensus toward $20 normalized EPS; a Q2 miss would re-open the credibility ledger, put the $172 technical breakdown level back in play, and push consensus FY27 EPS toward $7-8.
7. What Would Change the View
The two or three observable signals that would most change the underwriting debate over the next six months are: (1) the Q3 2026 consolidated MCR print — directly tests the cyclical-recovery thesis (long-term driver #3) and is the explicit convergence point for both the bull primary catalyst ("Q3 MCR below 91.0%") and the bear primary trigger ("Q3 MCR at or above 92.6%"); (2) the Washington Medicaid RFP filing in Q4 2026 — opens the single biggest five-year underwriting test (long-term driver #1, the incumbency moat), since a WA loss combined with the Virginia precedent rebases the RFP win-rate prior from "compounding" to "eroding" and forces a re-rate of the post-OBBBA revenue base; and (3) the Hindlemann motion-to-dismiss ruling — a denial would mark the moment the credibility discount on FY2026 / FY2027 guidance language is set and compounds with the active officer/director derivative investigations. Florida's Q4 go-live and the 1/1/2027 OBBBA + D-SNP + MAPD complex are larger in dollar terms but resolve on a slower cadence; they sit on the watchlist, not the trigger list. The current setup is a cycle-turn debate operating against an unresolved credibility ledger — one clean quarter without retro adjustments and a clean Washington RFP outcome would close it; a single retro hit or a denied MTD reopens it.